You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)公布艾伏尼布與阿扎胞(甘)聯合治療研究積極數據
阿思達克 08-04 08:26
基石藥業(02616.HK)合作夥伴全球製藥公司施維雅宣布,艾伏尼布(ivosidenib片劑)與化療藥物阿扎胞(甘)聯合治療先前未經治療的易感異檸檬酸脫氫(酉每)-1(「IDH1」)突變急性髓系白血病(「AML」)成人患者的全球III期雙盲安慰劑對照AGILE研究達到了無事件生存期(「EFS」)這一主要終點。與阿扎胞(甘)聯合安慰劑相比,艾伏尼布聯合阿扎胞(甘)治療在EFS中取得了具有統計學意義的改善。 此外,該試驗達到了其所有關鍵的次要終點,包括完全緩解(「CR」)率、總生存期(「OS」)、CR和伴部分血液學恢復的完全緩解(「CRh」)率以及客觀緩解率(「ORR」)。艾伏尼布聯合阿扎胞(甘)的安全性與先前公布的數據一致。由於治療組與對照組之間存在臨床重要性差異,根據獨立資料監測委員(「IDMC」)的建議,該研究近期提前停止入組。(sw/W)~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account